Pfizer is betting on 5 bio generic drugs

Source: Xinkangjie 2015-11-6 at present, Pfizer is betting on funds from bio generic drug manufacturers The company hopes that its bio generic drugs will cause effects in the U.S market after being listed At present, the company has five monoclonal antibodies under development As expected, these products are mainly targeted at the world's best sellers Pfizer's biosimilars are the best-selling monoclonal antibodies of meropene and Herceptin in recent years The original manufacturers of the two drugs are Baijian Aidi and Roche, respectively Of course, they also include the infliximab of Johnson / MSD These products are currently in phase III clinical trials In addition, Pfizer imitated Roche's Avastin has just completed phase I clinical trials in the near future, and the Sumerian generic drug with annual sales of more than 11 billion US dollars is in the early stage of trial Diem Nguyen, general manager of Pfizer biosimilars, said that Pfizer has prepared the funds for the group, and the R & D experience is not a problem for the company Pfizer is actively cooperating with the local market, including recruiting patients for clinical trials, and taking many measures to protect the safety of patients and attract them to the trials Nguyen believes that Pfizer's professionalism in the field of treatment, as well as its advanced R & D capability, technology and production capacity, combined with the advantages of global layout, will be able to provide patients with good drugs and meet the interest demands of investors Now the scope of treatment options is wider, which is undoubtedly great good news for our patients However, the long-term success of biosimilars will depend on the confidence of patients and doctors, and Nguyen said how to choose the market is also a key factor in determining success Pfizer recently created a website, which mainly provides information about the company's bio generic drugs and the R & D and production process, which helps patients better understand Pfizer's bio generic drugs For Pfizer, the launch of biosimilars is a big event, because in the U.S market as the base of Pfizer, according to the data of allied marketing research, the sales volume of biosimilars will reach 35 billion dollars in 2020 The best-selling biologics will face the impact of patent expiration from then on, and large pharmaceutical companies, such as Novartis and hospita, have taken up another position In July this year, Novartis became the first company to apply for the listing of bio generic drugs and obtain FDA approval The CEO of Novartis previously said that regulatory pressure and public response will be the key to the success of bio generic drugs in the short term, and the long-term return will be huge By 2020, five years from now, we can see the huge impact of bio generic drugs on the market At the same time, pharmaceutical companies are exploring emerging markets, which are potential markets for bio generic drugs Before that, Epirus Biopharmaceutics, a biopharmaceutical manufacturer based in Boston, and its Indian partner rambsi, jointly launched a biopharmaceutical that imitates the weight-bearing drug of Johnson & Johnson rheumatoid arthritis, Lek, which will go on the market a quarter earlier than expected At that time, Indian patients will be able to use the reduced price of Lek.